Bristol Myers Squibb (BMY) Other Working Capital Changes (2009 - 2026)
Bristol Myers Squibb's (BMY) quarterly Other Working Capital Changes came in at $3.6 billion in Q3 2012, up 17328.57% year-over-year from N/an in Q4 2011, and up 8313.95% quarter-over-quarter from $43.0 million in Q2 2012.
Analysis
Bristol Myers Squibb (BMY) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Other Working Capital Changes for 4 consecutive years, with $3.6 billion the latest figure, recorded in Q3 2012.
- On a quarterly basis, Other Working Capital Changes rose 17328.57% year-over-year to $3.6 billion in Q3 2012; TTM through Dec 2012 was $3.6 billion, a 3204.35% increase from a year earlier, with the FY2012 full-year figure at $3.6 billion, up 3204.35% from the prior year.
- Other Working Capital Changes was $3.6 billion for Q3 2012 at Bristol Myers Squibb, up from $43.0 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1.6 billion in Q1 2026 and troughed at -$1.1 billion in Q4 2025.
- A 5-year average of $57.3 million and a median of -$170.0 million in 2023 frame the typical range for Other Working Capital Changes.
- Across the five-year window, Other Working Capital Changes sank 262.86% in 2011 and surged 17328.57% in 2012, its largest moves.
- Over 4 years, Other Working Capital Changes stood at $60.0 million in 2009, then jumped by 93.33% to $116.0 million in 2010, then slumped by 96.55% to $4.0 million in 2011, then surged by 90350.0% to $3.6 billion in 2012.
- The last three Other Working Capital Changes figures came in at $3.6 billion (Q3 2012), $43.0 million (Q2 2012), and -$91.0 million (Q1 2012), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -786.00 Mn |
| Jun 30, 2026 | -786.00 Mn |
| Mar 31, 2026 | 1.64 Bn |
| Mar 31, 2026 | 1.64 Bn |
| Dec 31, 2025 | -1.07 Bn |
| Dec 31, 2025 | -1.07 Bn |
| Sep 30, 2025 | -240.00 Mn |
| Sep 30, 2025 | -240.00 Mn |
| Jun 30, 2025 | -222.00 Mn |
| Jun 30, 2025 | -222.00 Mn |
| Mar 31, 2025 | 1.06 Bn |
| Mar 31, 2025 | 1.06 Bn |
| Dec 31, 2024 | -725.00 Mn |
| Dec 31, 2024 | -725.00 Mn |
| Sep 30, 2024 | -167.00 Mn |
| Sep 30, 2024 | -167.00 Mn |
| Jun 30, 2024 | -340.00 Mn |
| Jun 30, 2024 | -340.00 Mn |
| Mar 31, 2024 | 608.00 Mn |
| Mar 31, 2024 | 608.00 Mn |